Results 171 to 180 of about 160,542 (279)

Long-Term Response to Pembrolizumab in Metastatic Metaplastic Breast Carcinoma: A Case Report. [PDF]

Am J Case Rep
Oshima Y, Suzuki T, Fukaya Y, Hosoya K, Tanaka Y, Wakahara M, Umekita Y, Tanaka Y.   +7 more
europepmc   +1 more source

Inflammatory Markers‐Based Surgical Pathological Complete Response Prediction After Neoadjuvant Immunotherapy Combined With Chemotherapy in Head and Neck Squamous Cell Carcinoma

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective To explore the predictive value of blood routine parameters for surgical pathological complete response (PCR) following neoadjuvant immunotherapy combined with chemotherapy (NICC) in patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC).
Yu‐Dong Ning, Yi‐Xuan Song, Han Li, Yu‐Qin He, Shao‐Yan Liu   +4 more
wiley   +1 more source

Indirect Comparison of the Efficacy of Pembrolizumab Versus Nivolumab as Adjuvant Options for Stage IIB/IIC Melanoma. [PDF]

Target Oncol
Andreikos DA, Argyropoulou I, Theocharopoulos C, Anastasopoulou A, Stefanou D, Lyrarakis G, Schadendorf D, Gogas H, Ziogas DC.   +8 more
europepmc   +1 more source

Cost‐Effectiveness Analysis of Transoral Robotic Surgery Versus Radiotherapy Alone for Early‐Stage HPV‐Associated Oropharynx Squamous Cell Carcinoma in Australia

Journal of Medical Imaging and Radiation Oncology, EarlyView.
ABSTRACT Introduction Transoral robotic surgery (TORS) and radiotherapy are both recognised as effective treatment options for early‐stage HPV‐associated oropharyngeal squamous cell carcinoma (HPV‐OPSCC). TORS offers the benefit of a shorter total treatment duration; however, a proportion of patients require adjuvant radiotherapy with or without ...
Lan Gao, June Corry, Danny Rischin, Tao Xing   +3 more
wiley   +1 more source

Checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer: treatment strategies, specificities, and care management questions. [PDF]

ESMO Gastrointest Oncol
André T, Lonardi S, Zaanan A, Cohen R, Taieb J.   +4 more
europepmc   +1 more source

Impact of Metformin and Diabetes on Tumor Response to Total Neoadjuvant Therapy in Advanced Rectal Cancer: A Multicenter Retrospective Cohort Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In advanced rectal cancer patients receiving total neoadjuvant therapy (TNT), overall tumor response did not differ by diabetes status or metformin use. However, among diabetic patients, metformin use was associated with higher overall complete response rates. These findings suggest a potential benefit of metformin in enhancing TNT response in diabetic
Sergei Bedrikovetski, Mahima Raju, Tracy Fitzsimmons, Ishraq Murshed, Timothy J. Price, Michael Penniment, Sudarsha Selva‐Nayagam, Tarik Sammour   +7 more
wiley   +1 more source

Pembrolizumab-Induced Isolated Adrenocorticotropic Hormone (ACTH) Deficiency

Pembrolizumab is a programmed death 1 receptor (PD-1) inhibitor. It is used as immunotherapy in various cancers, including metastatic melanoma, non-small cell lung cancer, and, notably, high-risk triple-negative breast cancer.
Han, Hye Jeong, Alfares, Khalid
core  

Predictors of pathologic complete response in early-stage triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: a multi-institution study. [PDF]

Breast Cancer Res Treat
LeVee A, Santos B, Wong M, Ruel N, Schmolze D, Kang I, Tsai K, Mortimer J, McArthur H.   +8 more
europepmc   +1 more source

Benchmarked Colorectal Cancer Outcomes in a Metropolitan Hospital: A 5‐Year Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In metastatic disease, patients with lung‐only metastasis had the best 5‐year survival at 46.0% and curative‐intent approaches can dramatically improve survival. ABSTRACT Introduction Colorectal cancer (CRC) remains a major contributor to cancer‐related mortality worldwide, with survival influenced by many prognostic factors.
Jialin Du, Vincent Wang, Basil D'Souza, Russell Hodgson   +3 more
wiley   +1 more source

Pembrolizumab plus enfortumab vedotin in urothelial cancer

The combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive ...
Fiala, Ondrej, Bellmunt, Joaquim, Santoni, Matteo, Bamias, Aristotelis, Buti, Sebastiano, Santoni, Angela, Takeshita, Hideki, Massari, Francesco, Cerbone, Linda, Mollica, Veronica   +9 more
core